Initiating TD Management

CE / CME

eCase: Identifying TD and Initiating Management in Patients With Primary Mood Disorders

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Social Workers: 1.00 ASWB ACE CE Credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Psychologists: 1.00 APA CE Credit

Nurses: 1.00 Nursing contact hour, including 1.00 hour of pharmacotherapy credit 

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: September 30, 2022

Expiration: September 29, 2023

Jacob Ballon
Jacob Ballon, MD, MPH

Activity

Progress
1
Course Completed

References

References

  1. Debrey SM, Goldsmith DR. Tardive dyskinesia: spotlight on current approaches to treatment. Focus (Am Psychiatr Publ). 2021;19:14-23.
  2. Hauser RA, Truong D. Tardive dyskinesia: out of the shadows. J Neurol Sci. 2018;389:1-3.
  3. Woods SW, Morgenstern H, Saksa JR, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry. 2010;71:463-474.
  4. Carbon M, Hsieh CH, Kane JM, et al. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78:e264-e278.
  5. Solmi M, Pigato G, Kane JM, et al. Clinical risk factors for the development of tardive dyskinesia. J Neurol Sci. 2018;389:21-27.
  6. Ricciardi L, Pringsheim T, Barnes TRE, et al. Treatment recommendations for tardive dyskinesia. Can J Psychiatry. 2019;64:388-399.
  7. Pardis P, Remington G, Panda R, et al. Clozapine and tardive dyskinesia in patients with schizophrenia: a systematic review. J Psychopharmacol. 2019;33:1187-1198.
  8. Blackman G, Oloyede E, Horowitz M, et al. Reducing the risk of withdrawal symptoms and relapse following clozapine discontinuation-is it feasible to develop evidence-based guidelines? Schizophr Bull. 2022;48:176-189.
  9. Schultz JL, Killoran A, Nopoulos PC, et al. Evaluating depression and suicidality in tetrabenazine users with Huntington disease. Neurology. 2018;91:e202-e207.
  10. Deutetrabenazine prescribing information. North Wales, PA: Teva; 2017.
  11. Valbenazine prescribing information. San Diego, CA: Neurocrine Biosciences; 2017.
  12. Revet A, Montastruc F, Roussin A, et al. Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. BMC Psychiatry. 2020;20:308.
  13. Cardoff S, Mann S, Gorton G, et al. How to discuss informed consent about the risk of tardive dyskinesia. simpleandpractical.com/informed-consent-tardive-dyskinesia. Accessed September 18, 2022.
  14. Alty J, Cosgrove J, Thorpe D, et al. How to use pen and paper tasks to aid tremor diagnosis in the clinic. Pract Neurol. 2017 Dec;17:456-463
  15. Bera R, Franey E, Martello K, et al. TeleSCOPE: a real-world study of telehealth for the detection and treatment of drug-induced movement disorders. CNS Spectrums. 2022;2:250-250.
  16. Strassnig M, Rosenfeld A, Harvey PD. Tardive dyskinesia: motor system impairments, cognition and everyday functioning. CNS Spectr. 2018;23:370-377.
  17. Barksdale T. Abnormal Involuntary Movement Scale - Admin (AIMSDVD.Com). www.youtube.com/watch?v=_dnK578aZdo. Accessed September 13, 2022.
  18. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry. 1988;39:1172-1177.
  19. Cornett EM, Novitch M, Kaye AD, et al. Medication-induced tardive dyskinesia: a review and update. Ochsner J. 2017;17:162-174.
  20. Xu H, Qin H, Chen S, et al. Vitamin E in the treatment of tardive dyskinesia: a meta-analysis. Int Clin Psychopharmacol. 2022;37:60-66.
  21. Hazari N, Kate N, Grover S. Clozapine and tardive movement disorders: a review. Asian J Psychiatr. 2013;6:439-451.
  22. Hatcher-Martin JM, Armstrong KA, Scorr LM, et al. Propranolol therapy for tardive dyskinesia: a retrospective examination. Parkinsonism Relat Disord. 2016;32:124-126.
  23. Tetrabenazine prescribing information. Deerfield, IL: Lundbeck; 2017.
  24. McIntyre RS, Calabrese JR, Nierenberg AA, et al. The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder. J Affect Disord. 2019;246:217-223.
  25. Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174:476-484.
  26. Marder SR, Singer C, Lindenmayer JP, et al. A phase 3, 1-year, open-label trial of valbenazine in adults with tardive dyskinesia. J Clin Psychopharmacol. 2019;39:620-627.
  27. Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4:595-604.
  28. Fernandez HH, Factor SA, Hauser RA, Jet al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology. 2017;88:2003-2010.
  29. Lin CC, Ondo WG. Non-VMAT2 inhibitor treatments for the treatment of tardive dyskinesia. J Neurol Sci. 2018;389:48-54.